ACM
KROS icon

ADAR1 Capital Management’s Keros Therapeutics KROS Stock Holding History

ADAR1 Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-300
Closed -$17.4K – 260
2024
Q3 		$17.4K Buy
+300
New +$14.8K ﹤0.01% 244

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

ADAR1 Capital Management's KROS Position: Q1 2026 in Review

ADAR1 Capital Management increased its Keros Therapeutics (KROS) stake by 416% in Q1 2026, buying an estimated $1.21M and bringing the position to 97,318 shares worth $1.07M. The position accounts for 0.06% of the portfolio, ranked #151.

ADAR1 Capital Management first reported a position in KROS in Q4 2023 and has held it in 10 quarters since. The position peaked at $85.3M in Q3 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • ADAR1 Capital Management held 97,318 shares of Keros Therapeutics worth $1.07M as of Q1 2026.
  • ADAR1 Capital Management bought 78,467 Keros Therapeutics shares in Q1 2026, an estimated $1.21M.
  • Keros Therapeutics made up 0.06% of ADAR1 Capital Management's portfolio in Q1 2026, its #151 holding.
  • ADAR1 Capital Management first reported a position in Keros Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • ADAR1 Capital Management's Keros Therapeutics position peaked at $85.3M in Q3 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.